Experts advised the FDA to withdraw a preterm birth treatment from the market; the Novavax booster for COVID-19 was approved by US regulators on Wednesday; allergy medication was found to be commonly present in those who died of an opioid overdose.
A panel of experts voted 14-1 to recommend withdrawing hydroxyprogesterone caproate (Makena), a treatment intended to prevent preterm birth, from the market, according to The Washington Post. The decision came as the panel of experts concluded that Makena was not an effective treatment. The drugmaker Covis Pharma, as well as some clinicians and patient groups, argued in the 3 days of hearings that the drug may work in a narrower population, including African American women. The FDA experts concluded that no data supported this argument. Although the recommendations of the panel do not constitute an official FDA decision, the FDA tends to follow the direction of the panel.
The FDA approved the Novavax COVID-19 booster to be used in adults 18 years and older, according to AP News. The FDA said that this booster is aimed at adults who cannot get the updated versions of the Pfizer and Moderna boosters that target the Omicron variant, whether it be for accessibility or medical reasons. The Novavax booster will be exclusively used as a first booster and cannot be used for people who have already had 1 or more boosters since their primary shot. The Novavax booster is a protein-based vaccine rather than a vaccine using mRNA, as the Pfizer and Moderna vaccines are.
Allergy medications, such as antihistamines, could be involved in the death toll of the opioid epidemic, according to USA Today. A total of 18% of people who died of a drug overdose between 2019 and 2020 also tested positive for antihistamines. More than 71% of the people who died had diphenhydramine, or Benadryl, in their bodies at the time of death. Drugs like diphenhydramine, which are sedating antihistamines, can exacerbate respiratory depression caused by opioids, which can lead to decreased breathing in the victim. Opioid overdoses can be treated with naloxone, but naloxone has no effect on antihistamines, which can lead to lethal outcomes.
Aetna Announces Simplified Access to Fertility Services
August 27th 2024Aetna has become the first major US insurer to expand access to fertility services by covering intrauterine insemination as a medical benefit for all eligible plans, marking a significant move toward greater equity in family-building options for people of all backgrounds.
Read More
Contributor: The Impact of Social Determinants of Health on Maternal Health
August 13th 2024While resources and strategies to combat social determinants of health do exist, effectively leveraging them requires a coordinated approach involving supportive policies, technical assistance, community governance, and sustainable financing.
Read More
Addressing Maternal Mortality in Medicaid by Focusing on Mental Health
February 15th 2023On this episode of Managed Care Cast, we speak with Inland Empire Health Plan, a managed care plan serving more than 1.4 million residents on Medi-Cal in California, about a new maternal mental health program aimed at supporting new mothers, both before they give birth and afterward.
Listen
CMS Unveils Proposed 2025 Physician Fee Schedule, Maternal Health Standards
July 11th 2024The 2025 Physician Fee Schedule includes a conversion factor reduction, expanded behavioral health services, extended telehealth waivers, new Quality Payment Program pathways, and measures to address suspect billing, alongside a Biden administration initiative introducing federal maternal health standards for hospitals.
Read More
Deductible Double Jeopardy: Patients May Pay More Out of Pocket When Pregnancy Crosses 2 Years
June 11th 2024This cross-sectional analysis of commercially insured delivering mothers suggests that greater out-of-pocket spending is incurred when pregnancy spans 2 years, causing them to face out-of-pocket limits twice.
Read More